<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5472">
  <stage>Registered</stage>
  <submitdate>22/02/2007</submitdate>
  <approvaldate>22/02/2007</approvaldate>
  <nctid>NCT00439621</nctid>
  <trial_identification>
    <studytitle>Safety Study of Anti-IgE Immunotherapy in Allergic Patients</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2006-24</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Allergy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - RP 01

Experimental: 1 - 

Experimental: 2 - 

Experimental: 3 - 

Placebo Comparator: 4 - 


Other interventions: RP 01
Active immunotherapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse Events</outcome>
      <timepoint>0-12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immune kinetic parameters</outcome>
      <timepoint>0-12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Allergy to at least one aero allergen

          -  Increased serum IgE level</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis of asthma

          -  Recent use of systemic corticosteroids or immunosuppressive treatment

          -  Allergy vaccination therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>42</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Resistentia Pharmaceuticals AB</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate safety and efficacy of three doses and two dosing
      regimens of RP01 as an anti-IgE immunotherapy in allergic patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00439621</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vidar Wendel-Hansen, MD, PhD</name>
      <address>Resistentia Pharmaceuticals AB</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>